L01XX40

26833-87-4

ceflatonin

synribo

myelostat

omacetaxine mepesuccinate

cephalotaxus alkaloid

hht

cgx-635

nsc-141633

Homoharringtonine, AKA HHT or omacetaxine mepesuccinate, is a cephalotaxine ester and protein synthesis inhibitor with established clinical activity as a single agent in hematological malignancies. Homoharringtonine is synthesized from cephalotaxine, which is an extract from the leaves of the plant, Cephalotaxus species. In October 2005, homoharringtonine received Orphan Drug designation from the EMEA for the treatment of chronic myeloid leukemia (CML). Then in March 2006, homoharringtonine received Orphan Drug status from the FDA for the treatment of CML. In November 2006, homoharringtonine, for the treatment of CML, was granted Fast Track designation by the FDA. Most recently, in October 2012, homoharringtonine was marketed under the brand name Synribo? and FDA approved for patients who are intolerant and/or resistant to two or more tyrosine kinase inhibitors used to treat accelerated or chronic phase CML.

InChI=1S/C29H39NO9/c1-27(2,33)8-5-10-29(34,16-23(31)36-4)26(32)39-25-22(35-3)15-28-9-6-11-30(28)12-7-18-13-20-21(38-17-37-20)14-19(18)24(25)28/h13-15,24-25,33-34H,5-12,16-17H2,1-4H3/t24-,25+,28-,29?/m0/s1

InChIKey=HYFHYPWGAURHIV-ZEDNPHJLSA-N

homoharringtonine

obo2:dinto_DB04865

homoharringtonine

[H][C@]12[C@H](OC(=O)C(O)(CCCC(C)(C)O)CC(=O)OC)C(OC)=C[C@@]11CCCN1CCC1=CC3=C(OCO3)C=C21

(2R,3S,6R)-4-methoxy-16,18-dioxa-10-azapentacyclo[11.7.0.0^{2,6}.0^{6,10}.0^{15,19}]icosa-1(13),4,14,19-tetraen-3-yl 1-methyl 3-hydroxy-3-(4-hydroxy-4-methylpentyl)butanedioate

C29H39NO9

RxList:http://www.rxlist.com/synribo-drug.htm

National Drug Code Directory:63459-177-14

PubChem Compound:72332

ChEBI:71019

ChemSpider:65276

PubChem Substance:11075063

Wikipedia:http://en.wikipedia.org/wiki/Omacetaxine_mepesuccinate

Drugs.com:http://www.drugs.com/cdi/omacetaxine-injection.html